What is Zacks Research's Estimate for BIO Q2 Earnings?

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Analysts at Zacks Research increased their Q2 2026 EPS estimates for Bio-Rad Laboratories in a research note issued to investors on Thursday, July 10th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.46 per share for the quarter, up from their prior forecast of $2.45. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q2 2027 earnings at $1.95 EPS.

BIO has been the subject of several other research reports. UBS Group dropped their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Royal Bank Of Canada dropped their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company dropped their price objective on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating for the company in a research note on Monday, June 9th. Wall Street Zen lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Citigroup decreased their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $324.25.

Bio-Rad Laboratories Price Performance

NYSE BIO traded down $6.05 during trading hours on Monday, hitting $250.92. 246,517 shares of the company's stock traded hands, compared to its average volume of 335,990. Bio-Rad Laboratories has a 52-week low of $211.43 and a 52-week high of $387.99. The company has a market capitalization of $6.83 billion, a PE ratio of -3.29 and a beta of 0.95. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.99 and a quick ratio of 4.43. The firm's 50-day moving average is $237.15 and its 200-day moving average is $268.72.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The business had revenue of $585.40 million during the quarter, compared to analysts' expectations of $573.01 million. During the same quarter in the previous year, the company earned $2.30 earnings per share. The company's quarterly revenue was down 4.2% on a year-over-year basis.

Hedge Funds Weigh In On Bio-Rad Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of BIO. Quarry LP acquired a new position in shares of Bio-Rad Laboratories in the 1st quarter worth approximately $29,000. GeoWealth Management LLC lifted its holdings in shares of Bio-Rad Laboratories by 342.9% in the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after acquiring an additional 72 shares during the last quarter. Picton Mahoney Asset Management lifted its holdings in shares of Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after acquiring an additional 35 shares during the last quarter. Curat Global LLC acquired a new position in shares of Bio-Rad Laboratories in the 1st quarter worth approximately $34,000. Finally, Allworth Financial LP lifted its holdings in shares of Bio-Rad Laboratories by 260.0% in the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company's stock worth $36,000 after acquiring an additional 104 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.